Morningstar Investment Management LLC Has $10.65 Million Stock Position in Johnson & Johnson $JNJ

Morningstar Investment Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 9.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,576 shares of the company’s stock after buying an additional 3,822 shares during the period. Johnson & Johnson comprises approximately 0.7% of Morningstar Investment Management LLC’s holdings, making the stock its 26th largest holding. Morningstar Investment Management LLC’s holdings in Johnson & Johnson were worth $10,652,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Pennington Partners & CO. LLC boosted its stake in shares of Johnson & Johnson by 64.7% in the 1st quarter. Pennington Partners & CO. LLC now owns 1,663 shares of the company’s stock valued at $406,000 after purchasing an additional 653 shares in the last quarter. Compound Planning Inc. increased its position in shares of Johnson & Johnson by 3.7% during the 1st quarter. Compound Planning Inc. now owns 61,390 shares of the company’s stock worth $15,006,000 after purchasing an additional 2,169 shares in the last quarter. Klingman & Associates LLC lifted its holdings in Johnson & Johnson by 1.6% during the 1st quarter. Klingman & Associates LLC now owns 18,072 shares of the company’s stock valued at $4,418,000 after purchasing an additional 280 shares during the last quarter. Modern Wealth Management LLC lifted its holdings in Johnson & Johnson by 4.0% during the 1st quarter. Modern Wealth Management LLC now owns 49,772 shares of the company’s stock valued at $12,150,000 after purchasing an additional 1,910 shares during the last quarter. Finally, Keebeck Wealth Management boosted its position in Johnson & Johnson by 30.1% in the first quarter. Keebeck Wealth Management now owns 8,840 shares of the company’s stock valued at $2,161,000 after buying an additional 2,043 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.6%

JNJ opened at $263.43 on Friday. Johnson & Johnson has a 1-year low of $164.23 and a 1-year high of $269.43. The stock has a market capitalization of $634.13 billion, a PE ratio of 30.52, a PEG ratio of 2.46 and a beta of 0.24. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The firm has a 50-day moving average price of $242.71 and a two-hundred day moving average price of $236.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the prior year, the business earned $2.77 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.68 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. TD Cowen raised their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Scotiabank reissued an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research report on Wednesday, July 15th. Argus raised their price target on Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Finally, Barclays lifted their price objective on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $265.30.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts highlighted that JNJ raised its outlook, with guidance upgrades adding to investor confidence after the company’s recent earnings beat. Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher
• Positive Sentiment: JNJ’s Innovative Medicine unit reported strong Q2 growth, helping show resilience even after Stelara patent loss and suggesting momentum can continue into the second half of 2026. J&J’s Innovative Medicine Unit Proves Its Resilience in Q2
• Positive Sentiment: Positive topline Phase 3 data for TECVAYLI and TALVEY showed large reductions in disease progression and death risk in relapsed/refractory multiple myeloma, strengthening JNJ’s oncology pipeline. TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
• Positive Sentiment: JNJ also received FDA De Novo authorization for its OTTAVA robotic surgical system, expanding its competitiveness in soft-tissue robotic surgery and broadening a potentially important growth platform. Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?
• Neutral Sentiment: Several articles framed JNJ as a defensive dividend stock and a steady healthcare holding, which reinforces its safe-haven appeal but is less likely to move the shares on its own. 3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
• Neutral Sentiment: Commentary on JNJ’s steadiness during market volatility and ETF exposure after earnings mainly reflects investor interest in the stock rather than a new fundamental change. ETFs to Buy Post JNJ’s Q2 Earnings Beat & Bullish 2026 Outlook

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.